Furthermore, Deng et al. also showed CDK4/6i palbociclib and abemaciclib significantly enhance T cell activation, contributing to anti-tumor effects in vivo, due in part to de-repression of nuclear factor of activated T cell family proteins and their target genes, critical regulators of T cell function [31]. Here, CDK4 is linked to neoplasm.